On September 17, CVS Health fell 3.06% in regular trading, trading at $91.58 per share, with turnover of $4.04 billion. The broader Health Care Services sector weakened in tandem, with THE CIGNA GROUP declining 2.52% during the same session.

The selloff was driven by mounting concerns over competitive positioning in insurance operations and an unprecedented surge in employer contract reviews ahead of the 2027 benefits cycle. A recent UBS survey of 166 benefits managers found that CVS Health and Cigna face greater pressure on their insurance businesses, even as their pharmacy benefit management arms remain competitive. Notably, CVS Health's Aetna unit scored highest in care and disease management, but trailed Elevance Health and UnitedHealth in overall insurer rankings. Approximately 77% of surveyed employers indicated plans to seek new proposals for 2027 core medical benefits, up sharply from 53% the prior year, intensifying competitive headwinds.

Adding to near-term pressure, CVS Health had warned during its Q2 earnings call that its Caremark PBM business would see membership declines next year, while 340B drug discount program headwinds are expected to persist into 2027, compounding uncertainty around forward earnings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)